The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage
Introduction
Invasive pneumococcal disease (IPD) is a major cause of morbidity and mortality in children and the elderly [1]. Vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Europe in 2001. In countries including PCV7 in the vaccination schedule there was a significant decrease in IPD incidence, mainly due to reductions in PCV7 serotypes in children aged <5 years, and in other age groups in which indirect effects were observed [2], [3]. However, replacement by non-PCV7 serotypes was observed in vaccinated children, mainly caused by serotypes 19A and 7F [4], [5]. PCV7 was replaced by the 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) to provide protection against additional serotypes.
Before July 2016, neither PCV7 nor PCV13 was included into routine vaccination schedule in Catalonia. Both vaccines were recommended by the Vaccination Advisory Committee of the Spanish Association of Pediatrics when they were licensed [6]. However, prior to July 2016, the governmental health plan paid for pneumococcal vaccination only for children younger than 5 years old with selected risk factors.
As vaccination of infants with pneumococcal conjugate vaccines may influence the distribution of serotypes in adults, changes in serotype distribution in this age group should be monitored. Until the PCV13 became available for adults, the 23-valent pneumococcal polysaccharide vaccine (PPV23) was recommended for people aged ≥65 years and <65 years at increased risk of IPD in the United States [7] and several European countries [8].
The objective of this study was to assess the impact of PCV13 on the incidence of IPD and serotype distribution in all age groups in a region with intermediate levels of pneumococcal conjugate vaccination.
Section snippets
IPD surveillance system
Catalonia is a region in the northeast of Spain with a registered population of 7,518,903 in 2014, distributed as follows: 147,572 children aged <2 years, 248,228 children aged 2–4 years, 5,785,820 people aged 5–64 years and 1,337,283 aged ≥65 years [9].
In July 2016, PCV13 was included in the Catalan vaccination schedule. The estimated PCV7 coverage in children aged <5 years with one or more doses in 2007–2009 was 58.7% (80.2% of them fully vaccinated) [10]. In 2013 the estimated coverage of
Baseline characteristics
Overall, 9338 IPD cases were reported between 2006 and 2014, of which 5461 (58.5%) were male. The age distribution was: 706 (7.6%) in the <2 years, 614 (6.6%) in the 2–4 years, 4137 (44.3%) in the 5–64 years and 3840 (41.1%) in the ≥65 years age groups. The age was unknown in 41 cases (0.4%). The mean age increased from 49.07 years (SD: 29) to 54.78 years (SD: 27.96) in 2006–2009 and 2010–2014, respectively (p < 0.001).
Pneumonia was the most common clinical presentation (73.9%, of which
Discussion
The overall incidence of IPD decreased by 26% in 2010–2014, mainly in children aged <5 years but also in non-vaccinated age groups. The overall reduction in IPD incidence was due to a reduction in specific PCV13 serotypes (44%) in both, the vaccinated and non-vaccinated age groups, which suggests that vaccinating children indirectly protected adults via herd immunity. In contrast, there was an increase in some non-PCV13 serotypes, suggesting serotype replacement, especially in adults aged
Conclusions
After the introduction of PCV13 vaccination, a decrease of 26% in the overall incidence of IPD was observed due to the reduction in PCV13 serotypes, suggesting herd immunity. Non-PCV13 serotypes increased in adults aged ≥65 years, suggesting serotype replacement.
Intermediate vaccination coverage provides fewer direct and indirect benefits than those observed in countries with greater coverage rates. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age
Conflicts of interest
The authors have no conflicts of interest to declare.
Acknowledgements
This study was partially funded by SpIDnet (Assessing the impact of vaccination with the conjugate vaccines on the epidemiology of invasive pneumococcal disease in Europe), a network funded by the European Centre for Disease Prevention and Control; the Catalan Agency for the Management of Grants for University Research (AGAUR Grant number 2017/SGR 1342); the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP CB06/02/0076); and the Centro de Investigación
References (36)
- et al.
Serotype replacement in disease after pneumococcal vaccination
Lancet
(2011) - et al.
Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona
J Infect
(2009) - et al.
Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes
Vaccine
(2013) - et al.
Effect of high valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study
Lancet Respir Med
(2017) - et al.
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Lancet Infect Dis
(2015) - et al.
Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain
J Infect
(2011) - et al.
Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013
Vaccine
(2014) - et al.
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
Lancet Infect Dis
(2015) - et al.
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
Vaccine
(2013) - et al.
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
Vaccine
(2011)
Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study
Vaccine
Secular trends (1990–2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination
Vaccine
Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine
Clin Microbiol Infect
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
J Infect Dis
Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study
Clin Infect Dis
Cited by (36)
Infectious Disease Prevention Group: Update on vaccines, 2022
2022, Atencion PrimariaAssociation of Bacteremia with Vaccination Status in Children Aged 2 to 36 Months
2021, Journal of PediatricsInfluence of pneumococcal vaccination on the hospitalization of healthy pediatric patients due to typical Community-Acquired Pneumonia
2020, International Journal of Infectious DiseasesCitation Excerpt :PCV-10 vaccine was commercialized with private funding from 2009 to 2014, but it was not very popular, considering that PCV-13 appeared on the market just one year later. There are numerous studies (Angoulvant et al., 2014; Picazo et al., 2017; Picazo et al., 2013; Olarte et al., 2017; Griffin et al., 2014; Shaughnessy et al., 2016; Ciruela et al., 2018; van Deursen et al., 2017; Jimenez Trujillo et al., 2017) in which differences are compared between the incidences of IPD and hospitalizations due to pneumonia in the pre- and post-VCN7 periods, and pre- and post-PCV-13 periods, however, there are no publications on these periods in our health area. This study's objective is to measure the impact on hospitalization and to describe clinical, epidemiological and prognostic factors of pediatric patients (3 months–14 years old) admitted to hospital for typical Community-Acquired Pneumonia in the years following the introduction of the new pneumococcal conjugate vaccines (PCV).
Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Guidelines. 2020 Update
2020, Archivos de Bronconeumologia